NASDAQ:SMMT Summit Therapeutics Q3 2026 Earnings Results & Report $16.17 +0.37 (+2.34%) Closing price 04:00 PM EasternExtended Trading$16.06 -0.12 (-0.71%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Summit Therapeutics beat analyst earnings expectations in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.20 versus the -$0.2817 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market Closes Summit Therapeutics EPS ResultsActual EPS-$0.20Consensus EPS -$0.2817Beat/MissBeat by +$0.0817One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersSummit Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$111 thousandBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Summit Therapeutics Q3 2026 Earnings FAQ Did Summit Therapeutics beat earnings estimates for Q3 2026? Summit Therapeutics (NASDAQ:SMMT) reported earnings of -$0.20 per share for Q3 2026, beating the consensus estimate of -$0.2817. The report was announced on Wednesday, November 4, 2026. Summit Therapeutics Earnings HeadlinesSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 20262 hours ago | businesswire.comSummit Therapeutics (SMMT) Could Be 46% Undervalued On New Cancer Trials And AI DealOctober 30, 2026 | finance.yahoo.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 4 at 1:00 AM | Behind the Markets (Ad)Summit Therapeutics (NASDAQ:SMMT) Stock Breaks Above Two Hundred Day Moving Average - Time to Sell?October 30, 2026 | americanbankingnews.comIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 SOctober 25, 2026 | gurufocus.comIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in ChinaOctober 25, 2026 | businesswire.comSee More Summit Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Summit Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Summit Therapeutics and other key companies, straight to your email. Email Address About Summit TherapeuticsSummit Therapeutics (NASDAQ:SMMT) Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases. Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings. Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company. Akeso retains rights in China, while Summit is responsible for development and commercialization activities across its licensed international territories. The company has roots in the United Kingdom and was historically involved in developing treatments for infectious diseases before shifting its strategic focus to oncology. Summit is led by Robert W. Duggan, who serves as chairman and chief executive officer, and conducts its clinical development and business activities through operations serving global markets.View Summit Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
